This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
2 mg homepage banner_mugs

About EYLEA® (aflibercept) 2 mg

NOT CURRENTLY PROMOTED BUT STILL AVAILABLE 

EYLEA® (aflibercept) 2 mg is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to myopic choroidal neovascularisation (myopic CNV).

 

EYLEA 2 mg Summary of Product Characteristics 

EYLEA 2 mg Prescribing Information

HAVE YOU THOUGHT ABOUT INTRODUCING EYLEA 8 MG?

EYLEA 8 mg Banner Image 2000x2000px

PERFORMANCE YOU CAN TRUST

Give your eligible patients up to 6 months in nAMD and DMO, and up to 5 months in RVO between treatment visits through fast and sustained drying, with 4x the molar dose of a tried-and-tested molecule.

  • Mean CRT reductions in the EYLEA 8 mg 8q8/3 arm (QUASAR) were -342.5 µm 4 weeks after 1 dose and reduction was maintained through to Week 64.
  • Mean CRT reductions in the EYLEA 8 mg 8q16 arm were -128 µm (PULSAR) and -127 µm (PHOTON) 4 weeks after 1 dose and reduction was maintained through Weeks 96-156.
Discover EYLEA® (aflibercept) 8 mg

EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to macular oedema secondary to retinal vein occlusion (branch, central and hemiretinal RVO).

 

Prescribing information for EYLEA® (aflibercept) 8 mg can be found here.

 

Abbreviations

8Q8, 2 mg every 8 weeks; 8Q8/3, aflibercept 8 mg administered every 8 weeks, after 3 monthly injections at 4-week intervals; 8Q16, 8 mg every 16 weeks; CRT, central retinal thickness; DMO, diabetic macular oedema; mCNV, myopic choroidal neovascularisation; nAMD, neovascular (wet) age-related macular degeneration; RVO, retinal vein occlusion.

PP-EYL-GB-3193 | July 2026

    • 1
      EYLEA® 40 mg/mL Summary of Product Characteristics.
    • 2
      EYLEA® 114.3 mg/mL Summary of Product Characteristics.
    • 3
      Korobelnik JF, et al. Ophthalmology 2026;133:39–50.
    • 4
      Do DV, et al. Ophthalmology 2025:S0161-6420(25)00707–9.
    • 5
      Chaudhary V, et al. Aflibercept 8 mg in macular edema following retinal vein occlusion: Week 64 results from the QUASAR trial. Angiogenesis, Exudation, and Degeneration. 7 February 2026. Virtual. Oral presentation.
    • 6
      Wong TY. Three-year outcomes of aflibercept 8 mg in nAMD: safety and efficacy results from the PULSAR extension study. Angiogenesis, Exudation, and Degeneration 2025. 8 February 2025. Virtual. Oral presentation.
    • 7
      Do DV. Aflibercept 8mg in DME: Key results from the PHOTON extension study. AAO 2024. 18–21 October 2024. Chicago, USA. Oral presentation.